EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy. We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW
Sachs Associates’ Post
More Relevant Posts
-
EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy. We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW
To view or add a comment, sign in
-
Modiblast Pharma GmbH is ready to advance into the clinical development phase with novel Dendritic Cell Therapies for liquid cancers. The focus is to target the core issue in acute myeloid leukemias (AML) and Myelodysplastic Syndromes (MDS): the extremely high rate of relapses after successful initial therapy. The Modiblast approach (3 patents granted) combines immunomodulators to induce blast cells to differentiate into leukemia-specific dendritic cells (DCleu) in the patient. This triggers both innate and adaptive immune cells in blood and tissue to kill remaining or recurring blasts and generates memory cells. Contrary to e.g. CAR-T there is no need to identify and select specific target molecules. And it doesn’t require complicated and expensive ex vivo cell extraction and preparation procedures and GMP facilities. Our long-term goal is to provide an easy-to-use self-administered drug that can stabilize remissions or halt progression of the diseases. This therapy may also normalize thrombocyte/neutrophil counts. The next step of clinical development is a Phase 1a/2b study which recently has passed BfArM scientific advice. Meet Modiblast Pharma GmbH @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW
To view or add a comment, sign in
-
Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Phialogics concept is based on the targeted modification of immunoglobulin receptor domains (IgVs) to modulate immune response in inflammatory diseases. IgV mediated receptor-ligand interaction represents a significant source of novel biologics. Phialogics lead molecules replicate endogenous protein-protein interactions to efficiently modulate the function of their target receptor. So far, only this unique platform technology can achieve such a high level of precision. Meet Phialogics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW
To view or add a comment, sign in
-
Check out the latest report from IMIR Market Research Pvt. Ltd. on the 𝗟𝗶𝘃𝗲𝗿 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 Outlook and Geography Forecast till 2028 Don't miss out on this opportunity to stay informed about the latest trends in the industry. Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test (Laboratory Tests {Biomarkers, Oncofetal and Glycoprotein Antigens, Enzymes and Isoenzymes, Growth Factors and Receptors, Molecular Markers, Pathological Biomarkers, Blood Tests, Imaging Tests, Endoscopy, Biopsy, Others}), By End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Pharmaceutical & CRO Laboratories) , COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028 📚 𝐆𝐞𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐩𝐫𝐢𝐜𝐞:👇 https://lnkd.in/dn48Crpn 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞::👇 Abbott Accuray BD Biocartis NV Biocept, Inc. . bioMérieux C. R. Bard GmbH. Danaher Corporation DIGNA BIOTECH Elekta Epigenomics AG Roche. Foundation Medicine GE HealthCare Hologic, Inc.. Illumina. Myriad Genetics. Oncimmune Perspectum Ltd QIAGEN Sirtex Medical Limited Sysmex Corporation #livercancer #cancer #breastcancer #lungcancer #cancerawareness #prostatecancer #liver #coloncancer #pancreaticcancer #liverdisease #cancersucks #stomachcancer #thyroidcancer #testicularcancer #livercancerawareness #hepatitisb #ovariancancer #cancersurvivor #braincancer #cancerresearch #skincancer #cancertreatment #cancerfree #cancerpatient #hbv #cancerfighter #oncology #liverhealth #leukemia #health
To view or add a comment, sign in
-
🔍 Exciting news in biotech investments! These investments show the growing potential in biometrics. Great to see advancements across different health areas, from mental health to cancer treatment 🇺🇸 Spyre Therapeutics | $180 million PIPE | monoclonal antibodies | preclinical in inflammatory bowel disease 🇺🇸 Engrail Therapeutics | $157 million series B | precision neuroscience | phase 2 in generalized anxiety disorder 🇨🇦 Cybin Inc | $150 million PIPE | mental healthcare | phase 2 in major depressive disorder 🇩🇪 Tubulis GmbH | €128 million ($138.75 million) series B2 | antibody drug conjugates | preclinical in multiple solid tumors 🇺🇸 Unicycive Therapeutics | $50 million PIPE | kidney disease treatments | phase 1 in hyperphosphatemia 🇬🇧 Relation | $35 million seed | multi omics for drug discovery | discovery in osteoporosis 🇸🇪 Asgard Therapeutics | €30 million ($32.53 million) series A | cancer immunotherapies | preclinical in cancer 🇬🇧 Mission Therapeutics | £25.2 million ($32 million) | deubiquitylating enzyme inhibitors | phase 2 in cardiac surgery-associated kidney injury 🇺🇸 Elicio Therapeutics | $6 million PIPE | immunotherapies | phase 2 in pancreatic ductal adenocarcinoma
To view or add a comment, sign in
-
PulseSight Therapeutics, launched early 2024, is an ophthalmology clinical-stage biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology for AMD. PulseSight has developed a proprietary platform that uses a user-friendly electro-transfection system to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle to treat eye diseases. The company’s lead program PST-611 in GA is ready to enter the clinic by the end of 2024, whilst its second program, PST-809 in wet AMD is at the very late stage of preclinical IND-enabling studies. Both first-in-class candidates benefit from a solid preclinical package showing their ability to address multiple pathological pathways involved in these two forms of AMD, thus providing a higher efficacy compared to current treatments. First clinical trials have been performed (PST-606 in non-infectious uveitis), showing the very good safety profile of both the plasmid and the delivery procedure as well as the long lasting expression of the therapeutic proteins, allowing to significantly reduce the frequency of injections (4 to 6 months). Pulsesight Therapeutics is managed by a highly experienced executive team and board of Directors; it is financed with seed investment from leading venture capital investors Dominik Escher, PhD, founding partner of Pureos Bioventures and Kostas Kaloulis, PhD, Venture Partner at ND Capital. Meet PulseSight Therapeutics @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW
To view or add a comment, sign in
-
𝙀𝙢𝙚𝙧𝙜𝙞𝙣𝙜 𝙏𝙧𝙚𝙣𝙙𝙨 𝙞𝙣 𝙩𝙝𝙚 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 𝙎𝙚𝙘𝙪𝙧𝙚 𝙖 𝙁𝙍𝙀𝙀 𝙎𝙖𝙢𝙥𝙡𝙚: https://lnkd.in/gUMXh-7X The 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 is experiencing dynamic growth, fueled by advancements in medical technology and a deeper understanding of neuro-oncology. As we navigate through 2024, several key trends are shaping the landscape: 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙫𝙚 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙩𝙞𝙘 𝙏𝙤𝙤𝙡𝙨: Cutting-edge imaging technologies, such as advanced MRI and PET scans, are revolutionizing the early detection of brain tumors. These tools enhance accuracy, allowing for timely intervention and improved patient outcomes. 𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 𝙏𝙝𝙚𝙧𝙖𝙥𝙞𝙚𝙨 & 𝙋𝙧𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚: The shift towards personalized medicine is leading to the development of targeted therapies that address specific genetic mutations and molecular characteristics of brain tumors. This approach is significantly improving treatment efficacy and minimizing side effects. 𝙄𝙢𝙢𝙪𝙣𝙤𝙩𝙝𝙚𝙧𝙖𝙥𝙮 & 𝙉𝙤𝙫𝙚𝙡 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩𝙨: Emerging therapies, including immunotherapy and gene editing techniques, are showing promise in treating brain tumors that were previously considered resistant to conventional methods. These innovative treatments offer new hope for patients. 𝙆𝙚𝙮 𝙋𝙡𝙖𝙮𝙚𝙧𝙨: The brain tumor diagnosis & therapeutics industry comprises of various key market players such as Pfizer, Amgen, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Karyopharm Therapeutics Inc., Canon Medical Systems Corporation, Lantern Pharma Inc. (Nasdaq: LTRN), and others. 𝘼𝙘𝙘𝙚𝙨𝙨 𝙁𝙪𝙡𝙡 𝙍𝙚𝙥𝙤𝙧𝙩: https://lnkd.in/g8vPGfFa As we move forward, collaboration between researchers, clinicians, and industry leaders will be crucial in advancing treatments and improving patient care. Let’s continue to support innovation and drive progress in this vital field! #braintumor #neurooncology #medicalinnovation #healthcare #precisionmedicine #immunotherapy #markettrends #marketresearch #globalindustry
To view or add a comment, sign in
-
𝙀𝙢𝙚𝙧𝙜𝙞𝙣𝙜 𝙏𝙧𝙚𝙣𝙙𝙨 𝙞𝙣 𝙩𝙝𝙚 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 𝙎𝙚𝙘𝙪𝙧𝙚 𝙖 𝙁𝙍𝙀𝙀 𝙎𝙖𝙢𝙥𝙡𝙚: https://lnkd.in/gUMXh-7X The 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 is experiencing dynamic growth, fueled by advancements in medical technology and a deeper understanding of neuro-oncology. As we navigate through 2024, several key trends are shaping the landscape: 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙫𝙚 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙩𝙞𝙘 𝙏𝙤𝙤𝙡𝙨: Cutting-edge imaging technologies, such as advanced MRI and PET scans, are revolutionizing the early detection of brain tumors. These tools enhance accuracy, allowing for timely intervention and improved patient outcomes. 𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 𝙏𝙝𝙚𝙧𝙖𝙥𝙞𝙚𝙨 & 𝙋𝙧𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚: The shift towards personalized medicine is leading to the development of targeted therapies that address specific genetic mutations and molecular characteristics of brain tumors. This approach is significantly improving treatment efficacy and minimizing side effects. 𝙄𝙢𝙢𝙪𝙣𝙤𝙩𝙝𝙚𝙧𝙖𝙥𝙮 & 𝙉𝙤𝙫𝙚𝙡 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩𝙨: Emerging therapies, including immunotherapy and gene editing techniques, are showing promise in treating brain tumors that were previously considered resistant to conventional methods. These innovative treatments offer new hope for patients. 𝙆𝙚𝙮 𝙋𝙡𝙖𝙮𝙚𝙧𝙨: The brain tumor diagnosis & therapeutics industry comprises of various key market players such as Pfizer, Amgen, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Karyopharm Therapeutics Inc., Canon Medical Systems Corporation, Lantern Pharma Inc. (Nasdaq: LTRN), and others. 𝘼𝙘𝙘𝙚𝙨𝙨 𝙁𝙪𝙡𝙡 𝙍𝙚𝙥𝙤𝙧𝙩: https://lnkd.in/g8vPGfFa As we move forward, collaboration between researchers, clinicians, and industry leaders will be crucial in advancing treatments and improving patient care. Let’s continue to support innovation and drive progress in this vital field! #braintumor #neurooncology #medicalinnovation #healthcare #precisionmedicine #immunotherapy #markettrends #marketresearch #globalindustry
To view or add a comment, sign in
-
Could a patient’s gut microbiome influence how they will respond to immunotherapy? Join Rachel Newsome, PhD, from Dr. Christian Jobin's lab at the Univ. of Florida, for a webinar on Feb. 21st featuring the findings from a study of Bacteroides-enhanced gut microbiomes associated with an enhanced response to anti-PD-1 therapy in NSCLC patients. Characterization of live Bacteroides isolates led to the discovery of a novel influential metabolite that stimulates IFNγ in CD8+ T cells, and in combination with anti-PD-1 therapy, significantly reduces tumor growth in a NSCLC mouse model. Save your seat for this informative discussion and learn about the high-throughput isolation and cultivation methods that, not only enabled this discovery, but can empower any microbiome-based product or drug development program. Register here: https://lnkd.in/g8dJcFYb #MicrobialIsolation #Immunotherapy #Microbiome #Webinar #DrugDiscovery #HighThroughputCultivation #Culturomics #Prospector
To view or add a comment, sign in
2,849 followers